After Leqembi approval, Eisai CEO to retire

Less than a week after Eisai secured a full approval for Leqembi — the first Alzheimer’s drug to achieve full approval — the drugmaker’s CEO announced his plan to retire by the end of July. 

Advertisement
By: Paige Twenter

Ivan Cheung, the CEO, president, senior vice president and chair of Eisai, will retire by July 31, according to a July 11 news release. Five executives were promoted, including Tatsuyuki Yasuno, who was CFO and is now acting president of the Americas and CEO and senior vice president of Eisai.

From manual to manageable: How AI and partnerships are transforming urology RCM

Recommended Whitepaper

Advertisement

Next Up in Pharmacy

  • CMS shares GLP-1 model: 7 notes

    CMS published plans Dec. 23 for its voluntary “Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth” — or BALANCE…

    By: Elizabeth Casolo
Advertisement

Comments are closed.